250 related articles for article (PubMed ID: 15062194)
1. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
Paumgartner G; Beuers U
Clin Liver Dis; 2004 Feb; 8(1):67-81, vi. PubMed ID: 15062194
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
4. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
[TBL] [Abstract][Full Text] [Related]
5. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
6. [Clinical pharmacology of ursodeoxycholic acid (UDCA)].
Kryczka W; Grieb P
Postepy Hig Med Dosw; 1994; 48(1):53-68. PubMed ID: 8058580
[TBL] [Abstract][Full Text] [Related]
7. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
9. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
[TBL] [Abstract][Full Text] [Related]
11. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
13. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
14. Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in Cholestatic Liver Disease.
Cifuentes-Silva E; Cabello-Verrugio C
Curr Protein Pept Sci; 2024; 25(3):206-214. PubMed ID: 37594109
[TBL] [Abstract][Full Text] [Related]
15. [Pathophysiology of cholestasis: correlation between bile acid metabolism and liver damage].
Stiehl A
Z Gastroenterol; 1992 Mar; 30 Suppl 1():46-8. PubMed ID: 1449016
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid in the treatment of chronic liver disease.
Cirillo NW; Zwas FR
Am J Gastroenterol; 1994 Sep; 89(9):1447-52. PubMed ID: 8079918
[TBL] [Abstract][Full Text] [Related]
17. Biliary physiology and disease: reflections of a physician-scientist.
Paumgartner G
Hepatology; 2010 Apr; 51(4):1095-106. PubMed ID: 20373364
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
19. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
Zollner G; Marschall HU; Wagner M; Trauner M
Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of cholestatic liver disease and therapeutic approaches.
Hirschfield GM; Heathcote EJ; Gershwin ME
Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
